<?xml version="1.0" encoding="UTF-8"?>


<article dtd-version="1.0" article-type="research-article">
  <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">nejeconbusi</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50000676</journal-id>
         <journal-title-group xmlns:xlink="http://www.w3.org/1999/xlink">
            <journal-title>Nebraska Journal of Economics and Business</journal-title>
         </journal-title-group>
      
         <publisher>
            <publisher-name>College of Business Administration of the University of Nebraska-Lincoln</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">01606557</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <volume xmlns:mml="http://www.w3.org/1998/Math/MathML"
                 xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">11</volume>
         <issue xmlns:mml="http://www.w3.org/1998/Math/MathML"
                xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">4</issue>
         <issue-id>i40020520</issue-id>
         <article-id pub-id-type="jstor">40472434</article-id>
         <title-group>
            <article-title>Price Competition and the Efficacy of Prescription Drugs: Conflicting Objectives?</article-title>
         </title-group>
         <contrib-group>
            <contrib>
               <string-name>
                  <given-names>Joseph M.</given-names>
                  <surname>Jadlow</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>10</month>
            <year>1972</year>
         </pub-date>
         <fpage>121</fpage>
         <lpage>133</lpage>
         <permissions>
            <copyright-statement>Copyright 1972 University of Nebraska-Lincoln</copyright-statement>
         </permissions>
         <self-uri xlink:href="https://www.jstor.org/stable/40472434"/>
      
      
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
  </front>
  <back>
    
      <fn-group xmlns:xlink="http://www.w3.org/1999/xlink">
        <title>[Footnotes]</title>
        <fn id="d57e107a1310">
            <label>1</label>
          
            <p>
               <mixed-citation id="d57e114" publication-type="other">
Hearings on Interagency Coordination in Drug Research and Regulation before
the Subcommittee on Reorganization and International Organizations of the Senate
Committee on Government Operations, Part 1, 87th Cong., 2d sess. (1963), p. 56.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e127a1310">
            <label>2</label>
          
            <p>
               <mixed-citation id="d57e134" publication-type="other">
Drug Amendments, 76 Stat. at L. 780 (1962).</mixed-citation>
            </p>
        </fn>
        <fn id="d57e141a1310">
            <label>3</label>
          
            <p>
               <mixed-citation id="d57e148" publication-type="other">
Federal Register 28 (January 8, 1963), p. 179.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e155a1310">
            <label>5</label>
          
            <p>
               <mixed-citation id="d57e162" publication-type="other">
Robert Dorfman and Peter 0. Steiner, "Optimal Advertising and Optimal Quality,"
American Economic Review 44 (December, 1954), pp. 826-836.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e173a1310">
            <label>7</label>
          
            <p>
               <mixed-citation id="d57e180" publication-type="other">
Edwin Mansfield, "Industrial Research and
Development: Characteristics, Costs, and Diffusion of Results," American Economic
Review 59 (May, 1969), pp. 65-71.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e193a1310">
            <label>8</label>
          
            <p>
               <mixed-citation id="d57e200" publication-type="other">
Howard A.Clymer, "The Changing Costs of Pharmaceutical Innovation," The
Economics of Drug Innovation, The Proceedings of the First Seminar on Economics
of Pharmaceutical Innovation, April 27-29, 1969, ed. Joseph D. Cooper (Washington,
D.C.: The American University, 1970), pp. 109-124.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e216a1310">
            <label>10</label>
          
            <p>
               <mixed-citation id="d57e223" publication-type="other">
Paul de Haen, Inc.,11 West 42nd Street, New York, New York 10036.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e230a1310">
            <label>12</label>
          
            <p>
               <mixed-citation id="d57e237" publication-type="other">
P. M. Costello, "Economics of the Ethical Drug Industry: A Reply to Whitney,"
Antitrust Bulletin 14 (Summer, 1969), pp. 397-403.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e247a1310">
            <label>14</label>
          
            <p>
               <mixed-citation id="d57e254" publication-type="other">
Martin Neil Baily, "Research and Development Costs and Returns: The U.S.
Pharmaceutical Industry," Journal of Political Economy 80 (January-February,
1972), pp. 70-85.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e267a1310">
            <label>15</label>
          
          
            <p>
               <mixed-citation id="d57e276" publication-type="other">
Estes Kefauver, In a Few Hands: Monopoly Power in America (Baltimore: Penguin
Books, 1965), p. 77.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e287a1310">
            <label>16</label>
          
            <p>
               <mixed-citation id="d57e294" publication-type="other">
Research and
Development in Industry (years 1961-1968).</mixed-citation>
            </p>
        </fn>
        <fn id="d57e304a1310">
            <label>17</label>
          
            <p>
               <mixed-citation id="d57e311" publication-type="other">
De Haen, Inc., op. cit.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e318a1310">
            <label>20</label>
          
            <p>
               <mixed-citation id="d57e325" publication-type="other">
Ibid.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e332a1310">
            <label>21</label>
          
            <p>
               <mixed-citation id="d57e339" publication-type="other">
Administered Prices:
Drugs for the Subcommittee on Antitrust and Monopoly of the Senate Committee
on the Judiciary, 87th Cong., 1st sess. (1961), pp. 226 and 250.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e352a1310">
            <label>22</label>
          
            <p>
               <mixed-citation id="d57e359" publication-type="other">
Paul de Haen, "The Impact of Modern Drugs on Society and on the
Drug Industry," Part Two, Drug and Cosmetic Industry 101 (1967), p. 54.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e369a1310">
            <label>23</label>
          
            <p>
               <mixed-citation id="d57e376" publication-type="other">
Ibid.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e384a1310">
            <label>24</label>
          
            <p>
               <mixed-citation id="d57e391" publication-type="other">
R. A. Gosselin and Co., Inc., National Prescription Audit: General Information
Report (1968), pp. 24-25.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e401a1310">
            <label>25</label>
          
            <p>
               <mixed-citation id="d57e408" publication-type="other">
Henry Steele, "Monopoly and Competition in the Ethical Drugs Market,"
Journal of Law and Economics 5 (1962), p. 133.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e418a1310">
            <label>26</label>
          
            <p>
               <mixed-citation id="d57e425" publication-type="other">
PMA, Prescription Drug Industry FACT BOOK (1968), p. 19, and Economic
Report of the President (1970), p. 229.</mixed-citation>
            </p>
            <p>
               <mixed-citation id="d57e434" publication-type="other">
John M. Firestone,
Department of Economics, The City College of the City University of New York,
January 23, 1971.</mixed-citation>
            </p>
        </fn>
        <fn id="d57e447a1310">
            <label>27</label>
          
            <p>
               <mixed-citation id="d57e454" publication-type="other">
Simon N. Whitney, "Economics of the Ethical Drug Industry:
A Reply to Critics," Antitrust Bulletin 13 (1968), pp. 803-848.</mixed-citation>
            </p>
        </fn>
      </fn-group>
    
  </back>
</article>


